Progress of resistance mechanisms of venetoclax in acute myeloid leukemia
10.3760/cma.j.cn115356-20230607-00131
- VernacularTitle:维奈克拉治疗急性髓系白血病耐药机制的研究进展
- Author:
Lihong ZONG
1
;
Huiying QIU
Author Information
1. 苏州大学附属第一医院血液内科 江苏省血液研究所 国家血液系统疾病临床医学研究中心 215006
- Keywords:
Leukemia, myeloid, acute;
Venetoclax;
Molecular targeted therapy;
Drug resistance
- From:
Journal of Leukemia & Lymphoma
2024;33(8):497-501
- CountryChina
- Language:Chinese
-
Abstract:
Venetoclax is a selective bcl-2 inhibitor that has shown promising efficacy in acute myeloid leukemia (AML) in combination with hypomethylating agents or low-dose cytarabine. However, the drug resistance remains major concern. This review provides a comprehensive summary of the known mechanisms of venetoclax resistance, so as to provide a reference for designing rational drug combination regimens.
